Background. Rotavirus vaccines have reduced moderate-to-severe gastroenteritis episodes in infants and young children. Nevertheless, knowledge gaps exist concerning rotavirus vaccine shedding and vaccine impact upon mild and asymptomatic wildtype infections. Our primary objective was to investigate vaccine shedding in Australian infants where the multivalent human-bovine reassortant rotavirus vaccine, RotaTeq, was part of the routine vaccination schedule.
Before Australia's rotavirus vaccine program began in mid-2007, rotavirus gastroenteritis led to 4% of children being hospitalized by age 5 years, 9% attending emergency departments, and 45% consulting their family doctor, with approximately 60% of these healthcare contacts occurring in the first 2 years of life [9] . In Queensland, Australia, RotaTeq was chosen for the state's publicly funded rotavirus vaccine program. This multivalent vaccine is given as a 3-dose schedule in the first 6 months of life and contains 5 live-attenuated human-bovine reassortant strains, 4 of which express 1 of the human virus VP7 outer capsid proteins, G1, G2, G3, or G4, while the fifth expresses the VP4 attachment protein, P [8] , derived from human parent strains [10] .
Within 18 months of commencing the statewide RotaTeq program, reported rotavirus cases had declined 65% in Queensland [11] and vaccine effectiveness for preventing rotavirus-coded hospitalizations was estimated at 94% in the first full-year vaccinated birth cohort [12] . In contrast with hospital-based data, little is known about the impact of rotavirus vaccines on mild gastroenteritis episodes managed within the community where clinical trial data suggest that vaccines are less efficacious [13] .
Changes in diagnostic testing practices have also occurred recently and may impinge upon monitoring vaccine effectiveness. In Queensland, and elsewhere, multiplexed real-time polymerase chain reaction (PCR) assays are replacing conventional methods for identifying gastrointestinal pathogens [14] . This poses a potential problem because RotaTeq as a live vaccine replicates within the gut and is shed in stools postvaccination where highly-sensitive assays may detect, but not discriminate between, vaccine and wild-type rotavirus strains.
The pivotal RotaTeq trial observed vaccine shedding in 13% of subjects following their first vaccine dose and none after the second and third doses using relatively insensitive viral culture techniques [2] . In contrast, a Taiwanese study adopting a vaccine strain-specific reverse-transcription PCR (RT-PCR) identified that 17 of 18 (94%) infants shed RotaTeq strains for 2-14 days after the first vaccine dose, and 2 infants were still shedding vaccine virus at 25 days [15] . Shedding was however, less frequent following the second (29/43 [67%] ) and third (23/36 [62%] ) doses, and confined to the first 2 weeks postvaccination. Nonetheless, there is some evidence that shedding may occur for longer periods as a study of infants hospitalized with respiratory infections reported vaccine virus shedding up to 8 months of age and 12 weeks after the third RotaTeq dose [16] .
Our primary objective was therefore to investigate the prevalence and duration of rotavirus vaccine shedding in an unselected community-based birth cohort of Australian infants. Secondary objectives were to record the incidence of wild-type rotavirus infections and to assess if semiquantitative estimates of viral load, determined by real-time RT-PCR cycle threshold (Ct) values, were positively associated with diarrheal symptoms and could differentiate between vaccine and wild-type strains.
METHODS

Study Design And Sample Collection
The Observational Research in Childhood Infectious Diseases (ORChID) Study (ClinicalTrials.gov: NCT01304914) is a community-based birth cohort study of infections in the first 2 years of life [17] . Women were approached antenatally and their infants enrolled at birth progressively from September 2010 to October 2012 at 2 hospitals (1 public and 1 private hospital) in Brisbane, a subtropical city in Queensland, Australia. Eligible infants were born at term (36-42 weeks) and needed to be healthy, without underlying chronic disorders or congenital abnormalities. Parents collected weekly stool swabs from their infants, beginning in the first week of life and ceasing at their second birthday. Swabs were mailed to our research laboratory, taking a median of 3 (interquartile range [IQR], 2-4) days for delivery, where they were processed and stored at -80°C. We and others have successfully used mailed swab specimens previously in community-based studies to detect rotavirus and other enteric agents [18, 19] . The infant's parents maintained a daily symptom diary, which included diarrhea as a data field, and this was returned by mail at the end of each month.
In Queensland, RotaTeq vaccine is given at 6-8 weeks, and at 4 and 6 months of age. RotaTeq vaccination status of study infants was reported by parents, and confirmed on the national, population-based Australian Immunisation Register. The Children's Health Queensland, Royal Brisbane and Women's Hospital, and University of Queensland human research ethics committees approved the study. Parents of each child provided written informed consent at enrollment.
Rotavirus Detection by RT-PCR and Genotyping Assays
Stool samples were made up to 10% suspensions by homogenizing in 2.5 mL S.T.A.R buffer (Roche Diagnostics, Castle Hill, Australia). The CAS1820 Xtractor Gene automated system (Qiagen, Australia) or MagNA pure 96 System (Roche Life Science, Australia) extracted viral RNA as per the manufacturer's instructions. Extraction efficiency and inhibition were assessed using an equine herpes virus spike [20] . Real-time RT-PCR testing was run for 45 cycles using previously published primers and probes targeting the rotavirus NSP3 region [21] , and was defined as positive if any virus was detected (Supplementary Methods). Ct values from real-time PCR for rotavirus-positive samples are inversely proportional to the amplified nucleic acid in the sample and were used as semiquantitative markers of viral load. Rotavirus positive samples were genotyped using a rotavirus vaccine strain-specific RT-PCR assay (RotaTeq VP6 RT-PCR) [22] and a genotyping method described previously targeting the rotavirus VP4 and VP7 regions [23] .
Definitions
A priori definitions for diarrhea, rotavirus detection, rotavirus episode, and symptomatic and asymptomatic episodes are provided in Table 1 .
Statistical Analysis
Summary statistics are reported as either mean (standard deviation) or median (IQR) values for continuous variables and frequency (percentage) for categorical variables. Linear regression models [24] .
Rotavirus detection Rotavirus was detected by reverse transcription polymerase chain reaction assay in a single sample.
Rotavirus episode
The period from the first to the last positive rotavirus samples. New episodes commenced from the first identification of a different rotavirus genotype, or identification of the same genotype >21-days from the last identification of the same genotype.
Symptomatic episode
A rotavirus episode where diarrhea occurred within ±7 days of the first rotavirus detection.
Asymptomatic episode
A rotavirus episode where diarrhea was not observed within ±7 days of the first rotavirus detection.
were used to investigate the following associations: (1) Ct values from successfully genotyped detections were compared to nongenotyped rotavirus detections; (2) shedding duration was compared between asymptomatic and symptomatic episodes; and (3) Ct values from the first rotavirus detection in asymptomatic episodes were compared with the first rotavirus detection from symptomatic episodes. Effect estimates are presented as mean difference and 95%
confidence interval (CI). All analyses were performed with Stata version 11.0 software (StataCorp, College Station, Texas).
RESULTS
Of 165 infants from 163 families enrolled in the study, one was excluded due to preterm birth and 6 failed to provide any swabs ( Figure 1 11 139 swabs (Figure 1, 66 .5% of maximum expected swabs; median, 85 swabs per child [range, 1-106 from birth until their second birthday]) with 67.7% followed until at least age 23 months (Supplementary Figure 1) . Their sociodemographic characteristics are presented in the Supplementary Table. Nine infants withdrew before the recommended age of the first RotaTeq dose, 3 did not receive the vaccine, and 10, 7, and 129 infants received 1, 2, and 3 doses, respectively (Supplementary Table) . Symptom diaries were submitted for 154 infants (Figure 1) , who provided 88 811 child-days of recorded observation from birth until their second birthday (79.4% of maximum expected; median, 730 [range, 1-730] days).
Rotavirus Detections
Overall, rotaviruses were detected in 1068 of 11 139 (9.6%) stool swabs from 139 infants. Genotyping was successful for 994 of 1068 (93.1%) specimens, with RotaTeq strains accounting for 951 of 994 (95.7%) of all rotavirus detections genotyped successfully. Of the 1068 rotavirus-positive detections, 1033 (96.7%) were in the first year of life.
Among the 951 typed as the RotaTeq vaccine strain, all but 3 were detected between 6 and 42 weeks of age in 136 of 146 (93.2%) infants who had received at least 1 vaccine dose ( Figure 2 ). In contrast, 43 (4.0%) wild-type strains from 20 infants were found throughout the first 2 years of life ( Figure 2 and Supplementary Figure 2) . These included G12P [8] (n = 28), G2P [4] (n = 11), G1P [8] (n = 3), and G4P [8] (n = 1). Except for 1 child who shed wild-type rotavirus before reaching the age of vaccination, all the other children with wild-type detections were vaccinated. 
Rotavirus Shedding
The cumulative proportions of infants shedding RotaTeq detected at least once after the first, second, and third doses were 87.0% (127/146), 57.4% (78/136), and 47.3% (61/129). The week-by-week proportion of vaccine-strain shedding in the 10 weeks following each dose is displayed in Figure 3 . The median duration of RotaTeq shedding was 3 (IQR, 1-8) weeks, 1.5 (IQR, 1-3) weeks, and 1 (IQR, 1-2) week after the first, second, and third doses, respectively. Maximum shedding durations were 13 (first dose), 9 (second dose), and 14 (third dose) weeks. In contrast, the median duration of rotavirus shedding after a wild-type infection was 1 (IQR, 1-3) week, with a maximum duration of 8 weeks. Although shedding was longer with symptomatic than asymptomatic episodes for both RotaTeq and wild-type detections, these differences were not statistically significant (Table 2 ). 
Rotavirus-Associated Symptoms
In the ORChID cohort of 263 rotavirus episodes (132 infants), there were 242 RotaTeq (132 infants) and 21 wild-type rotavirus episodes (19 infants) with corresponding symptom data ( Figure 3) .
DISCUSSION
Employing sensitive PCR assays, we detected rotaviruses in almost 10% of stool specimens collected weekly from ORChID participants during their first 2 years of life. These rotavirus-positive specimens were predominantly RotaTeq vaccine strains detected in asymptomatic infants and intensely clustered around the time of vaccination between 6 weeks and 8 months of age. The proportions of vaccinated infants shedding vaccine virus declined from 87.0% to 57.4% and 47.3% following the first, second, and third RotaTeq doses, respectively, and were still detected up to 14 weeks after the third dose. In contrast, wild-type strains were detected infrequently, but were observed throughout the first 2 years of life, and almost 1 in 4 episodes was associated with diarrhea. Mean Ct values were significantly lower in infants with symptomatic wild-type rotavirus episodes than those with either RotaTeq vaccine virus or asymptomatic wild-type detections. However, low RotaTeq Ct values were also observed in some infants, making these semiquantitative estimates of viral load in our hands an inadequate tool for differentiating between vaccine and wild-type viruses.
Previous studies investigating RotaTeq vaccine virus shedding have yielded mixed results depending upon the laboratory methods employed. Initial investigations relying upon culture-based methods only observed shedding in 8.9%-13% of infants in the week following their first vaccine dose [2, 25] . Subsequently, detections on at least 1 occasion increased to 21%-56% and 87%-94% of infants when either rotavirus antigen or RT-PCR assays were used respectively to test stools collected for 1-4 weeks after the first administered RotaTeq vaccine dose [15, 26, 27] . These time-limited investigations were, however, not designed to detect prolonged RotaTeq shedding by immunocompetent infants. Our study extends these earlier findings by showing not only that a high proportion of infants had RotaTeq detected in their stools postvaccination, but that the vaccine virus was also found in asymptomatic infants for several weeks afterward. This supports findings in Finnish infants hospitalized with respiratory infections, but without gastrointestinal symptoms, having RotaTeq detected in their stools up to 12 weeks after their last vaccination [16] . It is also consistent with post hoc studies of the pivotal RotaTeq field trial where the vaccine virus was detected in 75% of reanalyzed rotavirus antigen-positive stools collected from infants with gastroenteritis during the period they received the 3 doses of the active vaccine [2, 28] .
Our data indicate that there is little rotavirus-associated disease in high-income communities with high vaccine coverage. While Figure 3 . Proportion of children shedding vaccine strain after each multivalent human-bovine reassortant rotavirus vaccine dose. Only vaccine virus shedding within 0-10 weeks following vaccination is displayed. The days where positive samples fell between weeks postvaccination were rounded down to the preceding week. The cumulative proportions of infants shedding RotaTeq detected at least once after the first, second, and third doses were 87.0% (127/146), 57.4% (78/136), and 47.3% (61/129), respectively. This included 28 (19.2%) and 7 (5.1%) infants who were still shedding RotaTeq the week before their second and third vaccine doses, respectively. In the first stool swab collected after the second dose, the proportion of infants polymerase chain reaction (PCR) positive for RotaTeq was 46.3% (50/108) and 85.7% (24/28) for those who had and had not ceased shedding immediately prior to the second vaccine dose, respectively. Similarly, in the first stool swab collected after the third dose, the proportion of infants who were RotaTeq PCR positive was 36.1% (44/122) and 57.1% (4/7) for those who had and had not ceased shedding immediately before the third vaccine dose, respectively.
the incidence rate of wild-type rotavirus episodes by RT-PCR in the ORChID cohort was 10.3 episodes per 100 child-years, diarrhea associated with these strains in vaccinated infants was only 2.4 episodes per 100 child-years of observation. By comparison, a systematic review of studies before rotavirus vaccines were available estimated that the incidence of rotavirus gastroenteritis for children aged <2 years was 24 episodes per 100 child-years [29] . Thus, while rotavirus vaccination confers strong protection, subclinical and, occasionally, symptomatic infections may still occur after vaccination. This mimics the natural history of rotavirus where primary infection confers protection against subsequent severe disease and with each new exposure the risk of further rotavirus infection and diarrhea is reduced, but not eliminated [30] . Nevertheless, after several years there is a theoretical risk from diminished asymptomatic rotavirus circulation as reduced natural boosting could decrease population vaccine-induced immunity, leading to outbreaks in older susceptible children. Of further interest in the present study was that symptoms were also found in 2.5% of RotaTeq episodes, showing that vaccine-related diarrhea is uncommon, which is consistent with safety data from large field trials where, compared with placebo, those receiving RotaTeq had a slightly increased rate of diarrhea (10.4% vs 6.7%, respectively) in the week following the first vaccine dose [25] . Frequent detection of rotavirus in stools during the first 8 months of life following RotaTeq vaccination can make interpreting PCR results in infants with diarrhea difficult when assays do not distinguish between vaccine and wild-type rotavirus strains. This may lead to potential diagnostic delays and confusion in clinical practice [31] , while misclassification of cases risks underestimating effectiveness of vaccine programs [32] . Additional complexity is provided when PCR detects wild-type rotavirus in asymptomatic children [33] and for up to 8 weeks after recovering from gastroenteritis [34] . Assay diagnostic specificity can be improved by incorporating vaccine-specific probes into real-time multiplex PCR assays to detect gastrointestinal pathogens [22] . Others recommend Ct values of 24-27 as a semiquantitative measure of specimen viral load and marker of clinical significance [35, 36] . However, PCR assay performance characteristics vary and, in this study, although the mean Ct value for wild-type symptomatic episodes of 22.3 was almost 10 cycles lower than asymptomatic wild-type episodes, we were unable to identify a Ct value threshold for reliably distinguishing symptomatic and asymptomatic wild-type episodes. Moreover, there was no significant difference between the Ct values of RotaTeq symptomatic and asymptomatic episodes.
Rotavirus vaccines provide indirect protective effects for unvaccinated individuals [11] . As supported by our community-based study, this is attributed to herd protection from interrupted transmission of wild-type viruses. However, horizontal transmission of vaccine to unvaccinated contacts may also have a role since RotaTeq has been grown from stools collected in the first week postvaccination [2] , and transmission to siblings has occurred [37] . Our frequent detection of RotaTeq following vaccination indicates that further studies of vaccine virus transmission using both culture and PCR methods are needed to better understand this phenomenon.
The strengths of this single-center study include its intensive (weekly) sampling of a relatively large number of infants. Approximately three-quarters of infants completed at least 1 year of follow-up, allowing us to comprehensively examine the impact of rotavirus vaccine and rotavirus epidemiological trends in our sample. However, it also has several limitations. First, we relied upon parents to collect samples and to complete the symptom diaries. Although it had excellent completion, given the size and complexity of the study, not all diaries and specimens were returned. Furthermore, it is difficult to ascertain whether all samples were collected and handled appropriately, and if symptom diaries had accurate and complete documentation. Second, as stools swabs were collected weekly we may have underestimated the duration of RotaTeq shedding postvaccination. Third, although used widely [32, 35, 36, 38] , Ct values from real time RT-PCR are a proxy measure of viral load and can be influenced by individual assay performance characteristics and stool fluid composition. Nevertheless, large differences in Ct values are likely to be real. Fourth, we restricted this analysis to rotavirus virus only, and other potential causative agents of diarrhea symptoms have not been investigated at this time, potentially overestimating rotavirus-specific symptoms. Fifth, the absence of virus cultures meant we were unable to determine if we were measuring transmissible virus. Sixth, we did not seek to identify vaccine-derived reassortants in infants with either RotaTeq vaccine-associated symptoms or prolonged detection of RotaTeq in their stools [39] . Finally, this study involved only infants receiving RotaTeq, which does not replicate as efficiently in the gastrointestinal tract as Rotarix, the widely used single, live-attenuated, human-derived G1P [8] vaccine [40] . The limited data available, however, suggest that Rotarix is shed in higher quantities and potentially for longer periods than RotaTeq [15, 31, 40] .
In conclusion, our community-based birth cohort study of healthy infants found that RotaTeq nucleic acid was readily detected following vaccination, and detection following vaccination was more prolonged than documented previously in clinical trials and postlicensure studies. This has implications for interpreting diagnostic tests in infants, an age group commonly tested for rotavirus, and monitoring effectiveness of RotaTeq vaccine programs, while also highlighting the importance of better documentation and understanding of horizontal vaccine virus transmission. Nevertheless, in a setting with high RotaTeq coverage, symptomatic rotavirus disease was uncommon. Ongoing surveillance of circulating rotavirus genotypes remains important for understanding the different epidemiology of RotaTeq and wild-type rotavirus infections and monitoring the sustained effectiveness of rotavirus vaccine programs.
